Juzina

Sitagliptin Hydrochloride Monohydrate, the active ingredient in Juzina, is a DPP‑4 inhibitor presented as an oral dosage form for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to improve glycaemic control when used with diet and exercise.

GNH USA supplies Juzina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including regulatory support and temperature‑controlled shipping where required.

Juzina (sitagliptin) is used to improve glycaemic control in the type 2 diabetes therapeutic pathway. - Type 2 diabetes mellitus (monotherapy): lowers HbA1c and fasting plasma glucose when used alone with diet and exercise. - Type 2 diabetes mellitus (combination therapy): enhances glucose control when added to metformin or other antidiabetic agents. - Type 2 diabetes mellitus (renal impairment): provides glycaemic management with dose adjustment in patients with reduced kidney function.

Like all medications, Juzina may cause adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Nasopharyngitis: cold‑like symptoms. - Upper respiratory tract infection: mild cough or sore throat. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome: serious skin eruption. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: when combined with insulin or sulfonylureas.

Before initiating Juzina, clinicians should evaluate several safety considerations to minimise risk. - Renal function: assess baseline creatinine clearance and adjust dose in impairment. - Hepatic function: monitor liver enzymes in patients with liver disease. - Cardiovascular disease: use with caution in patients with unstable heart conditions. - Elderly patients: consider lower starting dose due to potential decreased clearance. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Juzina can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin: concurrent use may increase risk of hypoglycaemia. - Sulfonylureas: combined therapy can potentiate hypoglycaemic episodes.

Moderate Interactions (Monitor Closely): - Rifampin: enzyme induction may reduce sitagliptin plasma concentrations. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin exposure. - Diuretics (e.g., thiazides): may diminish glucose‑lowering effect.